Glioblastomas (GBM) are frequently resistant to immunotherapy. We showed that targeting regulatory T cells (Tregs) with an agonistic anti-GITR antibody reprograms tumor-infiltrating Tregs to effector cells, overcoming response to PD1 blockade in preclinical models of GBM.

The presence of drug efflux pumps that prevent drug accumulation in chemoresistant cancer cells is a cause of cancer treatment failure. We show that these drug pumps need mitochondrial ATP as fuel and that blocking mitochondrial ATP production with novel MCJ mimetics overcomes cancer chemoresistance

1 of the major un met need for patients with amyloidosis is earlier diagnosis. Currently 30% of patients succumb to the disease within the 1st year following diagnosis. This is because the diagnosis is delayed due to failure recognize.

The explosion of available data and revolution in algorithms have created a moment with infinite potential.

One of the most common cytogenetic abnormalities in myeloma is one of the most widely debated and poorly understood. We have summarized the literature of this mysterious genomic aberration and call for standardization as a key to understanding the significance of +1q and improving patient outcomes.